Meridian Bioscience Inc. logo

VIVO

Meridian Bioscience Inc.

$32.91

Earnings Summary

Revenue
$111.23Mn
Net Profits
$28.75Mn
Net Profit Margins
25.85%
PE Ratio
18.83

Highlights

Revenue:

Meridian Bioscience Inc.’s revenue jumped 30.45% since last year same period to $111.23Mn in the Q1 2022. On a quarterly growth basis, Meridian Bioscience Inc. has generated 25.91% jump in its revenue since last 3-months.

Net Profits:

Meridian Bioscience Inc.’s net profit jumped 9.31% since last year same period to $28.75Mn in the Q1 2022. On a quarterly growth basis, Meridian Bioscience Inc. has generated 87.43% jump in its net profits since last 3-months.

Net Profit Margins:

Meridian Bioscience Inc.’s net profit margin fell -16.2% since last year same period to 25.85% in the Q1 2022. On a quarterly growth basis, Meridian Bioscience Inc. has generated 48.86% jump in its net profit margins since last 3-months.

PE Ratio:

Meridian Bioscience Inc.’s price-to-earnings ratio after this Q1 2022 earnings stands at 18.83.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Meridian Bioscience Inc. post its latest quarter earnings

EPS Estimate Current Quarter
0.16
EPS Estimate Current Year
0.16

Highlights

EPS Estimate Current Quarter:

Meridian Bioscience Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.16 - a -66.67% fall from last quarter’s estimates.

EPS Estimate Current Year:

Meridian Bioscience Inc.’s earning per share (EPS) estimates for the current year stand at 0.16.

Key Ratios

Key ratios of the Meridian Bioscience Inc. post its Q1 2022 earnings

Earning Per Share (EPS)
0.66
Return on Assets (ROA)
0.12
Return on Equity (ROE)
0.19
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Meridian Bioscience Inc.’s earning per share (EPS) jumped 15.79% since last year same period to 0.66 in the Q1 2022. This indicates that the Meridian Bioscience Inc. has generated 15.79% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Meridian Bioscience Inc.’s return on assets (ROA) stands at 0.12.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Meridian Bioscience Inc.’s return on equity (ROE) stands at 0.19.

Dividend Per Share (DPS):

Meridian Bioscience Inc. declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-06
0.48
0.66
37.5%

Company Information

Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

Organisation
Meridian Bioscience Inc.
Headquarters
Cincinnati, Ohio, US
Employees
750
Industry
Health Technology
CEO
John Kenny